These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 29408302)

  • 21. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis.
    Heldin CH; Lennartsson J; Westermark B
    J Intern Med; 2018 Jan; 283(1):16-44. PubMed ID: 28940884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small molecule receptor tyrosine kinase inhibitor of platelet-derived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells.
    Li M; Ping G; Plathow C; Trinh T; Lipson KE; Hauser K; Krempien R; Debus J; Abdollahi A; Huber PE
    BMC Cancer; 2006 Mar; 6():79. PubMed ID: 16556328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dominant-negative mutations of platelet-derived growth factor (PDGF) receptors. Inhibition of receptor function by ligand-dependent formation of heterodimers between PDGF alpha- and beta-receptors.
    Ueno H; Escobedo JA; Williams LT
    J Biol Chem; 1993 Oct; 268(30):22814-9. PubMed ID: 8226792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PDGF receptors as targets in tumor treatment.
    Ostman A; Heldin CH
    Adv Cancer Res; 2007; 97():247-74. PubMed ID: 17419949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
    Koseła-Paterczyk H; Rutkowski P
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
    Roskoski R
    Biochem Biophys Res Commun; 2007 May; 356(2):323-8. PubMed ID: 17367763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
    George D
    Adv Exp Med Biol; 2003; 532():141-51. PubMed ID: 12908555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer.
    Lindmark G; Sundberg C; Glimelius B; Påhlman L; Rubin K; Gerdin B
    Lab Invest; 1993 Dec; 69(6):682-9. PubMed ID: 8264231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Tyr-762 in the platelet-derived growth factor alpha-receptor as the binding site for Crk proteins.
    Yokote K; Hellman U; Ekman S; Saito Y; Rönnstrand L; Saito Y; Heldin CH; Mori S
    Oncogene; 1998 Mar; 16(10):1229-39. PubMed ID: 9546424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
    Moawad EY
    J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ligand-induced interaction between alpha- and beta-type platelet-derived growth factor (PDGF) receptors: role of receptor heterodimers in kinase activation.
    Kanakaraj P; Raj S; Khan SA; Bishayee S
    Biochemistry; 1991 Feb; 30(7):1761-7. PubMed ID: 1847074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
    Roskoski R
    Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The involvement of platelet-derived growth factor receptors and insulin-like growth factor-I receptors signaling during mineralized nodule formation by human periodontal ligament cells.
    Nemoto E; Shimonishi M; Nitta Y; Shimauchi H
    J Periodontal Res; 2004 Dec; 39(6):388-97. PubMed ID: 15491343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Platelet- derived growth factor--the construction, role and it's receptors].
    Mantur M; Koper O
    Pol Merkur Lekarski; 2008 Feb; 24(140):173-6. PubMed ID: 18634279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.